NCT00085982View on ClinicalTrials.gov

Effect of Metreleptin Therapy in the Treatment of Severe Insulin Resistance

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

August 21, 2003

Primary Completion Date

October 23, 2019

Study Completion Date

January 1, 2030

Conditions
Severe Insulin Resistance
Interventions
DRUG

Metreleptin

Administered SC twice/day to achieve physiological concentrations that will be effective in improving the severe state of insulin resistance seen in patients with genetic defects on their insulin receptor mutation

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH